These sales are routine from a dollar and volume perspective and not indicative of negative sentiment given their small scale relative to company size. Traders should monitor for additional selling or commentary around earnings or pipeline updates.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $491.96entry
- T+1 · 8mo ago −2.84%α −1.36% · $477.98
- T+5 · 8mo ago −8.20%α −6.01% · $451.61
- T+20 · 7mo ago −9.21%α −9.74% · $446.63
- T+60 · 6mo ago −12.93%α −24.45% · $428.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Vertex Pharmaceuticals EVPs, the Chief Medical Officer and Chief Commercial Officer, sold shares in open-market transactions totaling approximately $2.45 million. The sales were modest in dollar value relative to the company's $118.4 billion market cap, representing just 0.002% of market value.
Key Financial Metrics
Key Facts
- EVP and CMO Carmen Bozic sold 2,329 shares for $1,122,088.91 on March 13, 2026, at $481.79 per share.
- EVP and Chief Commercial Officer Duncan McKechnie sold 2,633 shares for $1,312,339.86 on March 11, 2026, at $498.42 per share.
- Total insider sales in cluster: $2,434,428.77 across two C-suite executives.
- Sales represent approximately 0.002% of Vertex's $118.4B market cap, well below the 0.1% threshold for materiality.
Financial Impact
$2.43 million in total open-market sales by two executives
Risk Factors
- Perception risk if more executives sell in coming days.
- Potential misinterpretation as bearish signal despite lack of materiality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-VRTX-1773777879078 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers